CRC
MCID: CLR023
MIFTS: 97

Colorectal Cancer (CRC)

Categories: Genetic diseases, Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 57 38 12 75 37 29 13 13 55 6 43 15 63 73
Colon Cancer 57 12 75 29 55 6 15
Colon Carcinoma 12 55 15 73
Colorectal Carcinoma 12 55 73
Carcinoma of Colon 12 29 6
Colonic Adenoma Recurrence, Reduced Risk of 57 6
Colorectal Cancer, Susceptibility to 57 6
Colon Cancer, Susceptibility to 57 6
Colorectal Cancer, Somatic 57 13
Colon Cancer, Somatic 57 13
Colorectal Neoplasms 44 73
Colonic Neoplasms 44 73
Crc 57 75
Colon Cancer, Advanced, Somatic 57
Cancer, Colorectal, Somatic 40
Malignant Tumor of Colon 73
Colorectal Cancer. 6
Cancer, Colorectal 40
Colonic Carcinoma 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominantly acting oncogene plus loss of suppressor gene(s)


Classifications:



Summaries for Colorectal Cancer

PubMed Health : 63 About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare.Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps.Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy.In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and familial colorectal cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Colorectal Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include the colon, the rectum and colon, and related phenotypes are uterine leiomyosarcoma and renal cell carcinoma

OMIM : 57 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

UniProtKB/Swiss-Prot : 75 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

MedlinePlus : 43 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

Wikipedia : 76 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 36.8 APC BRAF CTNNB1 MLH1 MLH3 TP53
2 familial colorectal cancer 36.2 APC MLH1 TP53
3 familial adenomatous polyposis 35.5 APC CTNNB1 MCC MLH1 TP53
4 polyposis syndrome, hereditary mixed, 1 35.0 APC MLH1
5 mismatch repair cancer syndrome 34.9 APC CTNNB1 MLH1
6 adenoma 34.6 APC AXIN2 BRAF CTNNB1 MLH1 TP53
7 adenocarcinoma 34.2 APC BRAF CTNNB1 FGFR3 MLH1 PIK3CA
8 endometrial cancer 34.0 BAX BRAF CTNNB1 MLH1 MLH3 PIK3CA
9 hepatocellular carcinoma 34.0 APC BAX CTNNB1 DLC1 NRAS PDGFRL
10 familial adenomatous polyposis 1 33.7 APC CTNNB1
11 colon adenocarcinoma 33.7 BAX CTNNB1 MLH1
12 colorectal adenoma 33.6 APC CTNNB1 MLH1 TP53
13 lung cancer susceptibility 3 33.5 APC BRAF CTNNB1 FGFR3 NRAS PIK3CA
14 ovarian cancer 33.5 BAX BRAF CTNNB1 MLH1 PIK3CA TP53
15 lymphoma, non-hodgkin, familial 33.1 BAX BRAF NRAS PIK3CA RAD54B TP53
16 colorectal adenocarcinoma 33.0 BRAF CTNNB1 MLH1 TP53
17 hyperplastic polyposis syndrome 33.0 APC BRAF TP53
18 squamous cell carcinoma 33.0 BRAF CTNNB1 FGFR3 PIK3CA TP53
19 squamous cell carcinoma, head and neck 32.9 BRAF CTNNB1 FGFR3 PIK3CA TP53
20 esophageal cancer 32.9 BAX CTNNB1 DCC PIK3CA TP53
21 adrenocortical carcinoma, hereditary 32.8 BRAF CTNNB1 NRAS PIK3CA TP53
22 neuroblastoma 32.7 AXIN2 CTNNB1 NRAS PIK3CA TP53
23 cervical cancer 32.6 BAX CTNNB1 FGFR3 PIK3CA TP53
24 peutz-jeghers syndrome 32.4 APC CTNNB1 TP53
25 myeloma, multiple 32.3 BRAF FGFR3 NRAS TP53
26 uterine carcinosarcoma 32.0 CTNNB1 PIK3CA TP53
27 li-fraumeni syndrome 31.9 BAX MLH1 TP53
28 gastric adenocarcinoma 12.7 APC BAX BRAF CTNNB1 MLH1 NRAS
29 adamantinoma of long bones 12.6 APC BAX BRAF CTNNB1 MLH1 PIK3CA
30 colorectal cancer 12 12.5
31 colorectal cancer 1 12.4
32 colorectal cancer 3 12.4
33 skin melanoma 12.4 BRAF CTNNB1 MLH1 NRAS PIK3CA TP53
34 colorectal cancer 10 12.4
35 colorectal cancer, hereditary nonpolyposis, type 5 12.4
36 thyroid cancer 12.4 APC BRAF CTNNB1 NRAS PIK3CA TP53
37 bladder urothelial carcinoma 12.4 BRAF CTNNB1 FGFR3 NRAS PIK3CA TP53
38 colorectal cancer, hereditary nonpolyposis, type 8 12.4
39 colorectal cancer, hereditary nonpolyposis, type 6 12.4
40 colorectal cancer, hereditary nonpolyposis, type 4 12.4
41 colorectal cancer, hereditary nonpolyposis, type 7 12.4
42 renal cell carcinoma, papillary, 1 12.4 BRAF FGFR3 FLCN NRAS PIK3CA TP53
43 oligodontia-colorectal cancer syndrome 12.3
44 colorectal cancer, hereditary nonpolyposis, type 2 12.3
45 ovarian serous cystadenocarcinoma 12.3 BAX BRAF NRAS PIK3CA TP53
46 brain cancer 12.2 BRAF CTNNB1 NRAS PIK3CA TP53
47 colorectal cancer 2 12.2
48 colorectal cancer 5 12.2
49 bladder squamous cell carcinoma 12.2 BRAF EP300 FGFR3 PIK3CA TP53
50 lynch syndrome i 12.2

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectal Neoplasm
Rectosigmoid Junction Neoplasm Small Intestine Cancer
Splenic Flexure Cancer Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
hereditary nonpolyposis colorectal carcinoma
associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma
apc, ras, dcc or kras gene mutations
allele loss on chromosomes 5, 6, 12q, 15, 17, 18, or 22


Clinical features from OMIM:

114500

Human phenotypes related to Colorectal Cancer:

32
# Description HPO Frequency HPO Source Accession
1 uterine leiomyosarcoma 32 HP:0002891
2 renal cell carcinoma 32 HP:0005584
3 hereditary nonpolyposis colorectal carcinoma 32 HP:0006716
4 transitional cell carcinoma of the bladder 32 HP:0006740
5 neoplasm of the stomach 32 HP:0006753

UMLS symptoms related to Colorectal Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.07 EP300
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.07 PTPN12
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.07 NRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.07 NRAS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.07 NRAS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.07 EP300
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.07 EP300 NRAS APC PTPN12 BRAF
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 10.07 PTPN12
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.07 PTPN12
10 Decreased viability in esophageal squamous lineage GR00235-A 9.85 DLC1 TP53 FGFR3 MLH1 APC PIK3CA
11 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 TP53 EP300 MLH1 MLH3 BAX BRAF
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 DCC TP53 MLH1 PDGFRL BAX RAD54B
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 DCC TP53 MLH1 PDGFRL BAX BRAF

MGI Mouse Phenotypes related to Colorectal Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 PIK3CA NRAS MLH1 RAD54B TP53 BAX
2 growth/size/body region MP:0005378 10.44 PIK3CA NRAS FLCN PTPRJ PTPN12 TP53
3 mortality/aging MP:0010768 10.44 PIK3CA NRAS PTPN12 MLH1 RAD54B TP53
4 hematopoietic system MP:0005397 10.42 NRAS FLCN RAD54B PTPN12 TP53 PTPRJ
5 cardiovascular system MP:0005385 10.41 PIK3CA NRAS FLCN PTPRJ PTPN12 TP53
6 homeostasis/metabolism MP:0005376 10.41 MLH1 PIK3CA FLCN NRAS TP53 PTPRJ
7 embryo MP:0005380 10.38 PIK3CA NRAS PTPN12 TP53 PTPRJ AXIN2
8 immune system MP:0005387 10.37 PIK3CA NRAS FLCN PTPRJ PTPN12 TP53
9 endocrine/exocrine gland MP:0005379 10.34 MLH1 MLH3 PIK3CA NRAS TP53 APC
10 neoplasm MP:0002006 10.29 NRAS MLH1 PIK3CA TP53 PTPRJ BAX
11 craniofacial MP:0005382 10.27 NRAS TP53 AXIN2 APC CTNNB1 BRAF
12 digestive/alimentary MP:0005381 10.26 MLH1 NRAS TP53 APC CTNNB1 BRAF
13 nervous system MP:0003631 10.23 PIK3CA TP53 PTPN12 APC BAX AXIN2
14 integument MP:0010771 10.15 MLH1 PIK3CA NRAS TP53 APC CTNNB1
15 normal MP:0002873 10.14 NRAS MCC TP53 PTPRJ AXIN2 APC
16 muscle MP:0005369 10.1 PIK3CA TP53 PTPRJ APC BAX CTNNB1
17 no phenotypic analysis MP:0003012 10.09 PIK3CA NRAS PTPRJ PTPN12 TP53 APC
18 limbs/digits/tail MP:0005371 10.08 NRAS TP53 APC BAX AXIN2 CTNNB1
19 liver/biliary system MP:0005370 10.07 NRAS PTPRJ TP53 PTPN12 APC CTNNB1
20 hearing/vestibular/ear MP:0005377 10.06 TP53 APC BAX CTNNB1 BRAF FGFR3
21 reproductive system MP:0005389 10 MLH3 PIK3CA MLH1 PTPRJ TP53 BAX
22 renal/urinary system MP:0005367 9.92 FLCN TP53 APC BAX CTNNB1 BRAF
23 pigmentation MP:0001186 9.85 NRAS TP53 APC CTNNB1 BRAF DCC
24 respiratory system MP:0005388 9.81 MLH1 PTPRJ TP53 BAX BRAF CTNNB1
25 skeleton MP:0005390 9.61 PIK3CA NRAS TP53 APC BAX AXIN2
26 vision/eye MP:0005391 9.4 NRAS MLH1 PIK3CA TP53 BAX AXIN2

Drugs & Therapeutics for Colorectal Cancer

PubMedHealth treatment related to Colorectal Cancer: 63

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

FDA approved drugs:

(show all 12)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Avastin 18 49 BEVACIZUMAB Genentech July 2009
2
Campostar 18 49 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 18 Immunomedics April 1996
4
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
5
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
6
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
7
Vectibix 18 49 PANITUMUMAB Amgen September 2006
8
Xeloda 18 49 CAPECITABINE Roche April 1998/ May 2001
9
Zaltrap 18 49 ZIV-AFLIBERCEPT Sanofi-aventis August 2012
10
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
11
Iressa 18 49 GEFITINIB AstraZeneca May 2003
12
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 913)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-21-8 3385
2
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
3
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 17902-23-7 5386
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
5
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
6
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
7
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
9
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
10
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
11
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
12
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7553-56-2 807
13
Iron Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7439-89-6 23925
14
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
15
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 12560
16
Bisacodyl Approved Phase 4,Phase 3,Not Applicable 603-50-9
17
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
18
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
19
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
20
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 169590-42-5 2662
21
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 437-38-7 3345
23
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
24
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 2078-54-8 4943
25
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
26
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
29
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
30
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
31
Ketorolac Approved Phase 4,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
32
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
33
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6 23994
34
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
35
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
36
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
37
Magnesium citrate Approved Phase 4,Phase 3 3344-18-1
38
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
39
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
40
Udenafil Approved, Investigational Phase 4,Phase 2 268203-93-6 6918523
41
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
42
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 329-65-7 838
43
Ranibizumab Approved Phase 4,Phase 3 347396-82-1 459903
44
Sodium sulfate Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 7757-82-6
45
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 383414 6400441
46
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
47
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
48
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
49
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 93-14-1 3516
50
Methadone Approved Phase 4,Phase 1,Phase 2 76-99-3 4095

Interventional clinical trials:

(show top 50) (show all 5250)
# Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
3 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
4 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
5 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
6 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
7 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
8 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
9 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
10 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
11 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
12 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
13 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
14 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
15 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
16 Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function Unknown status NCT02231203 Phase 4 Omegaven;Placebo
17 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
18 Glucagon and Colonoscopy Unknown status NCT02078726 Phase 4 Glucagon;Placebo
19 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
20 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
21 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
22 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
23 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
24 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
25 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
26 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
27 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
28 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
29 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
30 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
31 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
32 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
33 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
34 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
35 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
36 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
37 Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Completed NCT01493713 Phase 4
38 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4
39 CHOICE: Communicating Health Options Through Information and Cancer Education Completed NCT00134589 Phase 4
40 A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
41 Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants Completed NCT00138060 Phase 4 irinotecan;5 fluorouracil
42 Nutrition for Colorectal Cancer Patients and Neutrophil Functions Completed NCT01831310 Phase 4
43 Chemotherapy Combined With CIK Treating Colon Cancer Completed NCT03084809 Phase 4 Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
44 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
45 Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery Completed NCT00488904 Phase 4
46 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4 Capecitabine
47 Inflammatory Response in Laparoscopic and Open Colectomy Completed NCT00942461 Phase 4
48 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
49 Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT Completed NCT00654212 Phase 4
50 Health Economic Evaluation of Primovist-enhanced Liver MRI Completed NCT00764621 Phase 4

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 29 AKT1 APC AXIN2 BUB1B CTNNB1 DCC DLC1 EP300 FGFR3 FLCN NRAS PIK3CA SRC TP53
2 Colon Cancer 29
3 Colorectal Cancer 29

Anatomical Context for Colorectal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

19
The Colon, The Rectum

MalaCards organs/tissues related to Colorectal Cancer:

41
Colon, Liver, Testes, Breast, Lung, Lymph Node, Endothelial

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 14606)
# Title Authors Year
1
Zerumbone, a Cyclic Sesquiterpene from Zingiber zerumbet Induces Apoptosis, Cell Cycle Arrest, and Antimigratory Effects in SW480 Colorectal Cancer Cells. ( 29276946 )
2018
2
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenoma. ( 29463834 )
2018
3
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. ( 29115526 )
2018
4
MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. ( 29156521 )
2018
5
Physical activity and the risk of colorectal cancer in Lynch syndrome. ( 29904935 )
2018
6
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer. ( 29408916 )
2018
7
Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT. ( 29656793 )
2018
8
Prognostic and clinicopathological value of p16 protein aberrant expression in colorectal cancer: A PRISMA-compliant Meta-analysis. ( 29561443 )
2018
9
Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice. ( 29976246 )
2018
10
Competing endogenous RNA network crosstalk reveals novel molecular markers in colorectal cancer. ( 29737552 )
2018
11
Risk of colorectal cancer in patients with periodontal disease severity: a nationwide, population-based cohort study. ( 29397431 )
2018
12
Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. ( 28045128 )
2018
13
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( 29159476 )
2018
14
Persuasion, Adaptation, and Double Identity: Qualitative Study on the Psychological Impact of a Screen-Detected Colorectal Cancer Diagnosis. ( 29977285 )
2018
15
Assessing the economic advantage of laparoscopic vs. open approaches for colorectal cancer by a propensity score matching analysis. ( 29110090 )
2018
16
Major improvement in the detection of microsatellite instability in colorectal cancer using HSP110 T17 E-ice-COLD-PCR. ( 29227006 )
2018
17
Is an Extensive ERAS Program Able to Bring a Better Outcome in Contrast With Standard ERAS Program for Laparoscopic Colorectal Cancer Surgery? ( 29975197 )
2018
18
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. ( 29975196 )
2018
19
Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases. ( 29977534 )
2018
20
Insulin receptor substrate-4 is overexpressed in colorectal cancer and promotes retinoblastoma-cyclin-dependent kinase activation. ( 29353348 )
2018
21
Impact of Metastasectomy in the Multimodality Approach for<i>BRAF</i>V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. ( 28904173 )
2018
22
Tri-Layer Polymeric Shells containing Magnetite Nanocarrier mediated LCS-1 delivery for Synthetic Lethal Therapy of BLM-defective Colorectal Cancer Cells. ( 29451980 )
2018
23
A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic Colorectal Cancer Model. ( 28643153 )
2018
24
Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening. ( 29976921 )
2018
25
TEMPORARY REMOVAL: Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway. ( 29339153 )
2018
26
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. ( 29261002 )
2018
27
Cost-effectiveness of colorectal cancer screening in Ukraine. ( 29977160 )
2018
28
Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients. ( 29277790 )
2018
29
Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. ( 29283894 )
2018
30
Epigenetic silencing of<i>SMOC1</i>in traditional serrated adenoma and colorectal cancer. ( 29435136 )
2018
31
Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. ( 28494536 )
2018
32
Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings. ( 29170881 )
2018
33
Neutrophil to Lymphocyte Ratio and C-Reactive Protein as Two Predictive Tools of Anastomotic Leak in Colorectal Cancer Open Surgery. ( 28132052 )
2018
34
Long noncoding RNAs: Undeciphered cellular codes encrypting keys of colorectal cancer pathogenesis. ( 29306015 )
2018
35
MicroRNA 26b promotes colorectal cancer metastasis by downregulating phosphatase and tensin homolog and wingless-type MMTV integration site family member 5A. ( 29160937 )
2018
36
The Role of <i>MTHFR</i> Genotype in Colorectal Cancer Susceptibility in Taiwan. ( 29599316 )
2018
37
Tumour Characteristics of Patients with Colorectal Cancer after Acute Uncomplicated Diverticulitis. ( 29945147 )
2018
38
Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer. ( 28710725 )
2018
39
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( 29450468 )
2018
40
Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. ( 29967423 )
2018
41
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
42
Genomic characterization of colitis-associated colorectal cancer. ( 29966533 )
2018
43
Identification of a fluorescent small-molecule enhancer for therapeutic autophagy in colorectal cancer by targeting mitochondrial protein translocase TIM44. ( 27849558 )
2018
44
LncRNALUADT1 is overexpressed in colorectal cancer and its expression level is related to clinicopathology. ( 29762830 )
2018
45
Multispectral imaging reveals hyper active TGF-I^ signaling in colorectal cancer. ( 29219668 )
2018
46
Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. ( 29327160 )
2018
47
Differences in gene mutations according to gender among patients with colorectal cancer. ( 29976257 )
2018
48
MiR-218 regulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via targeting CTGF. ( 29977158 )
2018
49
[Aspirin and colorectal cancer]. ( 29153543 )
2018
50
Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis. ( 29448935 )
2018